课题基金 / 基金详情

PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS

PROTEIN LIPID INTERACTIONS IN GALLSTONE PATHOGENESIS
胆结石发病机制中的蛋白质脂质相互作用
批准号:
6176189
负责人:
Nezam Hassan Afdahl
金额:
$23.12万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-07-15 至 2003-05-31

项目摘要

项目成果

Nezam Hassan Afdahl的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cholesterol gallstone disease is one of the commonest digestive diseases in the United States and results in 700,000 cholecystectomies annually with a direct health care cost in excess of $3 billion. Gallbladder mucin plays a central role in gallstone formation and this proposal will examine the mechanism by which mucin interacts with biliary lipids to promote gallstones. The specific Aims are to 1) Characterize the interaction of specific sites of the mucin molecule with lipid vesicles to improve our understanding of how mucin promotes crystallization of cholesterol monohydrate; 2) Characterize how mucin effects the morphology and rate of crystal growth in solution and in gels so that growth inhibitors can eventually be developed; 3) Examine the central role of mucin as the matrix protein in the biomineralization of both calcium and cholesterol. These Aim's will be achieved by utilizing multiple biophysical techniques to examine model systems where mucin and its modified structural forms will interact with biliary lipids similar to those seen in gallstone bile. Fluorescent assays, dynamic light scattering and magic angle spinning magnetic resonance will examine how mucin promotes vesicle fusion and sub- microscopic nucleation. Light and electron microscopy will examine the way in which mucin can promote both the pattern and rate of crystal growth. These studies may lead to strategies for the prevention and non-surgical therapy of this very common disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Core
CLINICAL TRIAL: PHASE I STUDY OF SILYMARIN IN CHRONIC HEPATITIS C OR FATTY LIVER
PHASE I STUDY OF SILYMARIN IN CHRONIC HEPATITIS C OR FATTY LIVER DISEASE
Clinical Center for Phase I/II trials of Silymarin in Chronic Liver Disease
海外基金